Using Apolipoprotein B to Manage Dyslipidemia

Computerized history-taking as a tool to manage dyslipidemia

BACKGROUND Validated guidelines to manage low-density lipoprotein (LDL)-cholesterol are utilized inconsistently or not at all even though their application lowers the incidence of coronary events. New approaches are needed, therefore, to implement these guidelines in everyday practice. METHODS AND RESULTS We compared an automated method for applying The National Cholesterol Education Panel (N...

The association between small dense low density lipoprotein,apolipoprotein B, apolipoprotein B/apolipoprotein A1 ratio and coronary artery stenosis

  Abstract   Background: Recently, small dense low density lipoprotein (sdLDL) has been   highlighted as a new risk factor for the coronary artery disease (CAD).Small dense   LDLs are believed to be atherogenic since these particles are taken up more easily by   arterial wall. They are readily oxidized and have reduced affinity for low density   lipoprotein (LDL) receptor and increased affinity...

Apolipoprotein E in Diabetic Dyslipidemia and Atherosclerosis

Apolipoprotein B Gene Polymorphisms and Dyslipidemia in HIV Infected Adult Zimbabweans

BACKGROUND Dyslipidemia does not occur in all HIV-infected or antiretroviral therapy-experienced patients suggesting role of host genetic factors but there is paucity of data on association between dyslipidemia and gene polymorphisms in Zimbabwe. OBJECTIVE To determine association of lipoprotein levels and apolipoprotein B polymorphisms in HIV-infected adults. METHOD Demographic data were c...

Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia.

HMG-CoA reductase inhibitors (statins) are effective lipid-altering drugs for the treatment of dyslipidemia in patients with type 2 diabetes mellitus. We conducted a randomized, double-blind, placebo-controlled, crossover design trial to determine the effects of simvastatin, 80 mg/day, on plasma lipid and lipoprotein levels and on the metabolism of apolipoprotein B (apoB) in VLDL, intermediate ...